Mario Grande Abascal

Mario Grande Abascal is currently the Director at Ikan Biotech. Mario has previously held positions at LiberaBio, Neurofix Pharma S.A., OXOLIFE, Aura Committed Medtech, Laminar Pharma, and Cinfa Biotech.

Mario has always been driven by their passion for the life sciences and their desire to make a difference in the world. After completing their degree in Business Administration, they began their career in the financial sector of the pharmaceutical industry. Mario quickly rose through the ranks, becoming the Corporate Financial Manager & Controller for Cinfa Group.

In 2013, Mario decided to leave the corporate world behind and pursue their dream of starting their own company. Mario co-founded OtCEM Pharmaceuticals S.L., where they served as the Financial Manager. The company developed and launched innovative and disruptive solutions with a big impact in key areas of health systems.

After a few years, Mario returned to the corporate world and took on the role of Board Observer for Aura Committed Medtech. During their time there, they helped the company develop and launch new products that had a positive impact on healthcare.

In 2019, Mario became a Board Member for Laminar Pharma. Mario held this position until 2021 when they took on their current role as Director at Ikan Biotech. Ikan Biotech is a biotechnology company that is developing lipid-based therapies for the treatment of neurological pathologies.

Mario Grande Abascal has a Bachelor of Arts in Business Management & Administration from Universidad Pública de Navarra. Mario also has an Advanced Management Program from Esade and a Business Angels School from Esade. Mario's focus is on Strategic Management and they have a Global Growth Strategy from The Wharton School.